MVP 1.16% 42.5¢ medical developments international limited

Another Positive Study, page-12

  1. 4,298 Posts.
    lightbulb Created with Sketch. 1491
    Must begetting close to some news on this.

    https://www.ema.europa.eu/en/docume...n-agreed-paediatric-investigation-plan_en.pdf
    Page 7

    Study 1
    A randomised, double blind, multi-centre, placebo-controlled study to evaluate the safety and efficacy of methoxyflurane for the treatment of acute pain in children from 12 to less than 18 years of age (and in adults) presenting to an Emergency Department with minor trauma (MEOF-001).

    Study 2
    A randomised, double-blind, multi-centre, placebo controlled study to evaluate safety and efficacy of methoxyflurane for the treatment of acute pain in children and adolescents from 6 to less than 18 years of age presenting to an Emergency Department with minor trauma (MEOF-002).

    Date of completion of the paediatric investigation plan: By July 2021
 
watchlist Created with Sketch. Add MVP (ASX) to my watchlist
(20min delay)
Last
42.5¢
Change
-0.005(1.16%)
Mkt cap ! $47.87M
Open High Low Value Volume
43.0¢ 44.0¢ 42.0¢ $35.10K 81.11K

Buyers (Bids)

No. Vol. Price($)
2 3150 42.5¢
 

Sellers (Offers)

Price($) Vol. No.
44.5¢ 29462 3
View Market Depth
Last trade - 16.10pm 19/11/2024 (20 minute delay) ?
MVP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.